Enanta Pharmaceuticals (NASDAQ:ENTA) Releases Quarterly Earnings Results

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) issued its quarterly earnings data on Monday. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.16) by $0.11, Zacks reports. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA traded up $1.64 during trading hours on Thursday, reaching $7.50. The stock had a trading volume of 2,001,273 shares, compared to its average volume of 570,597. Enanta Pharmaceuticals has a 1 year low of $4.71 and a 1 year high of $17.80. The firm's 50 day moving average is $5.75 and its 200-day moving average is $9.51. The stock has a market capitalization of $159.98 million, a price-to-earnings ratio of -1.37 and a beta of 0.54.

Insider Buying and Selling

In related news, CEO Jay R. Luly purchased 45,000 shares of the company's stock in a transaction on Wednesday, February 12th. The shares were bought at an average cost of $5.69 per share, for a total transaction of $256,050.00. Following the completion of the purchase, the chief executive officer now directly owns 846,638 shares of the company's stock, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 13.89% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ENTA. StockNews.com downgraded shares of Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday. JMP Securities reaffirmed a "market outperform" rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday. Robert W. Baird lowered their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a report on Tuesday, November 26th. Finally, HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Enanta Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $17.25.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.